Companies › SPH Qingdao Growful Pharmacetical
1 active drug program in 2 registered trials: 2 Phase 4; Cardiovascular; next expected readout Aug 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Yangxinshi tablet | – | Phase 4 | Coronary Heart Disease; Chronic Coronary Syndrome | Aug 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06171061 | Yangxinshi tablet | Phase 4 | Chronic Coronary Syndrome | Cardiovascular | Dec 2026 |
| NCT07110415 | Yangxinshi tablet | Phase 4 | Coronary Heart Disease | Cardiovascular | Aug 2030 |
No annotated target.
–
CeleCor Therapeutics MedTrace Pharma Hanlim Pharm. Trust Bio-sonics Liquidia Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.